Loading clinical trials...
Loading clinical trials...
Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.
The purpose of this study is to determine whether \[18F\]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials. In this phase 1 study we will assess the safety and biodistribution of \[18F\]FHBG in patients.
The success of cell and gene therapy depends on specific targeting of the therapeutic gene or cell that is administered to the patient. Our goal is to develop an imaging method to non-invasively monitor the location of the therapeutic gene or cell. Imaging should help in the design of better protocols and potentially reduce side-effects of cell and gene therapy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University of California Los Angeles
Los Angeles, California, United States
Stanford University School of Medicine
Stanford, California, United States
Start Date
April 1, 2005
Primary Completion Date
June 1, 2013
Completion Date
June 1, 2013
Last Updated
March 14, 2017
10
ACTUAL participants
[18F]FHBG
RADIATION
Lead Sponsor
Sanjiv Sam Gambhir
NCT07017686
NCT02691923
NCT05038553
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions